FFAR4 and polycystic ovary syndrome: By the fourth week of treatment, the PCOS-IR+GPR120 agonist group, the PCOS-IR+LrB (40 mg/kg) group, and the PCOS-IR+LrB (20 mg/kg) group all had significant reductions in body weight (Figure 2E); the PCOS-IR+LrB (10 mg/kg) group also showed significant decreases in body weight (Figure 2E).